Novozymes CEO: "We haven't met our targets in six years"

"We haven't invested enough, and we haven't been able to reap the fruits of the work we've done. That's why we have now laid a strategy to move away from this trend, to head in the right direction – toward growth," says Novozymes CEO Ester Baiget.


Danish enzyme producer Novozymes' new growth strategy, "Unlocking Growth – Powered by Biotech", stretching to the end of 2025, will pull the company out of an unfortunate trend, says Chief Executive Ester Baiget during the company's virtual capital markets day on Tuesday.

"We haven't met our targets in six years. One year is a point, two years is a line – but three years is a trend," she says about recent years' developments at Novozymes.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from EnergyWatch

Welcon's record revenue shaves paper-thin profit margin

State-subsidized steel from China is making the Danish wind turbine tower supplier's profit bottom out. If the EU doesn't decide to impose a tariff on Chinese steel this year, Welcon predicts that several suppliers will collapse. "But it won't be us," the CEO says.

Further reading

Related articles

Trial banner

Latest News

See all jobs